Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Year: 2017
Type: conference-abstract
Source: Cancer Research
Authors: Ryan J. Sullivan, Filip Janku, Bob T. Li, Deborah Wong, Jeffrey Sosman, Vicki Keedy, Elizabeth Buchbinder, Anthony Tolcher, Anna Varghese, David M. Hyman, Keith T. Flaherty, Antoni Ribas, Richard Carvajal, Andrea Wang-Gillam, Harriet Kluger, Manish Patel, Peter Langecker, Mary Varterasian, Dean Welsch, Jeffrey Infante
Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, Northwestern University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, South Texas Accelerated Research Therapeutics, Columbia University Irving Medical Center, Washington University in St. Louis, Yale Cancer Center, Sarah Cannon
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2740910319